I was just pondering why cf33 has had such early success with bile duct cancer.
And I wonder if it's because the number of cancerous cells are less.
Maybe bile duct cancer becomes noticed and impacts the body much sooner than other cancers.
Or perhaps it is a more localised cancer, and hence few cancerous cells.
Hence cf33 at lower doses is already able to win the battle, compared with other cancers where the cancerous cell numbers are higher (and higher cf33 doses will be needed).
Any thoughts from the brains trust on this idea?
I was just pondering why cf33 has had such early success with...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.5¢ |
Change
0.005(7.14%) |
Mkt cap ! $548.9M | |||
| Open | High | Low | Value | Volume |
| 7.1¢ | 7.6¢ | 7.1¢ | $1.896M | 25.79M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 3194318 | 7.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.6¢ | 331280 | 7 |
View Market Depth
| Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.6¢ |
Change
0.005 ( 6.34 %) |
||||
| Open | High | Low | Volume | ||
| 7.1¢ | 7.6¢ | 7.1¢ | 15199158 | ||
| Last updated 15.59pm 10/05/2024 ? | |||||
| IMU (ASX) Chart |